Study identifier:SH-QBE-0051
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A pharmacodynamic study comparing a 20 mg MUPS tablet with a 20 mg capsule of H 199/18 in patients with symptomatic gastroesophageal reflux disease
gastrointestinal diseases
N/A
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|